IRIS-Onyx Cohort in the IRIS-DES Registry

Sponsor
Seung-Jung Park (Other)
Overall Status
Recruiting
CT.gov ID
NCT02593994
Collaborator
CardioVascular Research Foundation, Korea (Other), Medtronic Korea Co., Ltd. (Other)
4,000
33
132
121.2
0.9

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the relative effectiveness and safety of Onyx stent compared to other (drug eluting stents) DES.

Condition or Disease Intervention/Treatment Phase
  • Device: Onyx Drug Eluting Stent group

Study Design

Study Type:
Observational
Anticipated Enrollment :
4000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Evaluation of Effectiveness and Safety of Resolute Onyx™ in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Actual Study Start Date :
Oct 1, 2015
Anticipated Primary Completion Date :
Sep 30, 2022
Anticipated Study Completion Date :
Sep 30, 2026

Arms and Interventions

Arm Intervention/Treatment
Onyx Drug Eluting Stent

Device: Onyx Drug Eluting Stent group

Outcome Measures

Primary Outcome Measures

  1. Stent thrombosis [1 year]

    As per Academic Research Consortium (ARC) standard, definite or probable stent thrombosis

Secondary Outcome Measures

  1. All death [5 year]

  2. Cardiac death [5 year]

  3. Myocardial infarction [5 year]

  4. Composite event of death or myocardial infarction [5 year]

  5. Composite event of cardiac death or myocardial infarction [5 year]

  6. Composite event rate [5 year]

    death, myocardial infarction, target vessel revascularization

  7. Target Vessel revascularization [5 year]

  8. Target Lesion revascularization [5 year]

  9. Stent thrombosis [5 year]

  10. Stroke [5 year]

  11. Procedural success [3 day]

    defined as less than 30% residual stenosis at the completion of procedure without death or Q wave myocardial infarction or urgent revascularization participants will be followed for the duration of hospital stay, an expected average of 3days.

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 19 and more

  • Intervention with Onyx Drug Eluting Stent

  • Agreed with written informed consent form

Exclusion Criteria:
  • Intervention with Onyx drug eluting coronary stent and other drug eluting stent at the same time

  • Life expectancy of 1year and under

  • Cardiac shock

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Catholic University of Korea, Yeouido St. Mary's Hospital Seoul Republic Of Korea Korea, Republic of
2 Asan Medical Center Seoul Songpa-gu Korea, Republic of 138-736
3 Hallym University Sacred Heart Hospital Anyang Korea, Republic of
4 Soon Chun Hyang University Hospital Bucheon Bucheon Korea, Republic of
5 Soon Chun Hyang University Hospital Cheonan Cheonan Korea, Republic of
6 Gangwon National Univ. Hospital Chuncheon Korea, Republic of
7 Daegu Catholic University Medical Center Daegu Korea, Republic of
8 Keimyung University Dongsan Medical Center Daegu Korea, Republic of
9 Chungnam National University Hospital Daejeon Korea, Republic of
10 The Catholic University of Korea, Daejeon ST. Mary's Hospital Daejeon Korea, Republic of
11 Gangneung Asan Hospital Gangneung Korea, Republic of
12 Chonnam National University Hospital Gwangju Korea, Republic of
13 Inje University Ilsan Paik Hospital Ilsan Korea, Republic of
14 Gachon University Gil Hospital Incheon Korea, Republic of
15 Inha University Hospital Incheon Korea, Republic of
16 Presbyterian Medical Center Jeonju Korea, Republic of
17 Kwangju Christian Hospital Kwangju Korea, Republic of
18 Dong-A Medical Center Pusan Korea, Republic of
19 Inje University Pusan Paik Hospital Pusan Korea, Republic of
20 Pusan National University Hospital Pusan Korea, Republic of
21 Gangnam Severance Hospital Seoul Korea, Republic of
22 Hallym University Kangnam Sacred Heart Hospital Seoul Korea, Republic of
23 Kangbuk Samsung Hospital Seoul Korea, Republic of
24 Kangdong Sacred Heart Hospital Seoul Korea, Republic of
25 Korea University Anam Hospital Seoul Korea, Republic of
26 Korea University Guro Hospital Seoul Korea, Republic of
27 The Catholic University of Korea Seoul St. Mary's Hospital Seoul Korea, Republic of
28 The Catholic University of Korea St. Paul's Hospital Seoul Korea, Republic of
29 St.carollo Hospital Suncheon Korea, Republic of
30 Bundang CHA Hospital Sungnam Korea, Republic of
31 Ulsan University Hospital Ulsan Korea, Republic of
32 Wonju Severance Christian Hospital Wonju Korea, Republic of
33 Pusan National University Yangsan Hospital Yangsan Korea, Republic of

Sponsors and Collaborators

  • Seung-Jung Park
  • CardioVascular Research Foundation, Korea
  • Medtronic Korea Co., Ltd.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Seung-Jung Park, MD, PhD, Asan Medical Center
ClinicalTrials.gov Identifier:
NCT02593994
Other Study ID Numbers:
  • AMCCV2015-04
First Posted:
Nov 1, 2015
Last Update Posted:
Sep 13, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Seung-Jung Park, MD, PhD, Asan Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 13, 2021